Barnidipine


Concise Prescribing Info
Indications/Uses
HTN.
Dosage/Direction for Use
Adult : PO Initial: 5-10 mg once daily. Maintenance: 10-20 mg once daily.
Dosage Details
Oral
Hypertension
Adult: Initially, 5-10 mg once daily, may increase dose according to response. Usual maintenance: 10-20 mg once daily.
Administration
May be taken with or without food.
Contraindications
Cardiogenic shock; recent MI or acute unstable angina; severe aortic stenosis.
Special Precautions
Hypotension, poor cardiac reserve, heart failure. Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischaemic pain following admin. Pregnancy, lactation.
Adverse Reactions
Dizziness; flushing; headache; hypotension; peripheral oedema; tachycardia; palpitations; GI disturbances; increased micturition frequency; lethargy; eye pain; depression; ischaemic chest pain; cerebral or myocardial ischaemia; transient blindness; rashes; fever; abnormal liver function; gingival hyperplasia; myalgia; tremor; impotence.
Drug Interactions
Other antihypertensives; aldesleukin; antipsychotics that cause hypotension; may modify insulin and glucose responses; quinidine; carbamazepine; phenytoin; rifampicin; cimetidine; erythromycin.
Lab Interference
Falsely elevated spectrophotometric values of urinary vanillylmandelic acid.
Action
Description: Barnidipine is a dihydropyridine calcium-channel blocker. It is a peripheral and coronary vasodilator, but has little or no effect on cardiac conduction and -ve inotropic activity is rarely seen at therapeutic doses. admin primarily results in vasodilatation, with reduced peripheral resistance, BP, and afterload, increased coronary blood flow, and a reflex increase in heart rate. This results in an increase in myocardial O2 supply and cardiac output.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Barnidipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in